No label defined (Q3179530)

From EU Knowledge Graph
Revision as of 19:15, 12 October 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): Objectives: Evaluate the capacity of structural and functional analysis of the retina and the retina nerve fiber layer as biological markers of axonal damage and progression of Parkinson’s disease. Analyse the ability of these retinal parameters to predict neurodegeneration, functional disability and quality of life impairment due to Parkinson’s disease. Design: Prospective cohort trial developed jointly by the Neurology, Ophthalmology and Neur...)
Jump to navigation Jump to search
Project Q3179530 in Spain
Language Label Description Also known as
English
No label defined
Project Q3179530 in Spain

    Statements

    0 references
    4,800.0 Euro
    0 references
    9,600.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2015
    0 references
    31 March 2018
    0 references
    INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD
    0 references

    41°39'7.67"N, 0°52'51.38"W
    0 references
    50297
    0 references
    Objetivos: Evaluar la capacidad del análisis estructural y funcional de la retina y de la capa de fibras nerviosas de la retina como marcadores biológicos de daño axonal y de progresión de la enfermedad de Parkinson. Analizar la capacidad de estos parámetros retinianos para predecir neurodegeneración, discapacidad funcional y afectación de calidad de vida por enfermedad de Parkinson. Diseño: Ensayo de cohortes prospectivo desarrollado conjuntamente por los Servicios de Neurología, Oftalmología y Neurofisiología. Se incluirán 200 pacientes con enfermedad de Parkinson y 200 controles sanos. Protocolo: Se realizará una valoración neurológica (con evaluación de severidad, discapacidad funcional y calidad de vida), una valoración oftalmológica (con tomografía de coherencia óptica y pruebas de función visual) y una valoración neurofisiológica (con potenciales evocados visuales y electrorretinograma pattern). Estas exploraciones se han realizado de modo basal en 2012-13 y, durante el desarrollo del estudio, se repetirán a los tres años. Posteriormente se desarrollarán algoritmos matemáticos para evaluar la capacidad de los parámetros retinianos en la predicción de severidad, grado de neurodegeneración y afectación de calidad de vida de los pacientes con enfermedad de Parkinson. Las pruebas para evaluar la retina y la capa de fibras nerviosas son inocuas, económicas y han demostrado ser buenos marcadores de degeneración axonal en la enfermedad de Parkinson, aunque se requieren estudios de seguimiento como éste para establecer su utilidad clínica. (Spanish)
    0 references
    Objectives: Evaluate the capacity of structural and functional analysis of the retina and the retina nerve fiber layer as biological markers of axonal damage and progression of Parkinson’s disease. Analyse the ability of these retinal parameters to predict neurodegeneration, functional disability and quality of life impairment due to Parkinson’s disease. Design: Prospective cohort trial developed jointly by the Neurology, Ophthalmology and Neurophysiology Services. 200 patients with Parkinson’s disease and 200 healthy controls will be included. Protocol: A neurological assessment (with evaluation of severity, functional disability and quality of life), an ophthalmological assessment (with optical coherence tomography and visual function tests) and a neurophysiological assessment (with visual evoked potentials and electroretinogram pattern) will be performed. These explorations were carried out at baseline in 2012-13 and, during the course of the study, will be repeated after three years. Subsequently, mathematical algorithms will be developed to evaluate the capacity of retinal parameters in predicting severity, degree of neurodegeneration and quality of life involvement of patients with Parkinson’s disease. Tests to evaluate the retina and the layer of nerve fibers are safe, economical and have been shown to be good markers of axonal degeneration in Parkinson’s disease, although follow-up studies such as this one are required to establish its clinical usefulness. (English)
    12 October 2021
    0 references
    Zaragoza
    0 references

    Identifiers

    PI14_01499
    0 references